Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living with HIV in Southern Africa.
Africa
CD4 lymphocyte count
Cohort studies
HIV infections
Southern
antiretroviral therapy
highly active
viral load
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
06
02
2020
revised:
06
05
2020
accepted:
19
05
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
13
5
2021
Statut:
ppublish
Résumé
The World Health Organization (WHO) recommends a CD4 cell count before starting antiretroviral therapy (ART) to detect advanced HIV disease, and routine viral load (VL) testing following ART initiation to detect treatment failure. Donor support for CD4 testing has declined to prioritize access to VL monitoring. We examined trends in CD4 and VL testing among adults (≥15 years of age) starting ART in Southern Africa. We analysed data from 14 HIV treatment programmes in Lesotho, Malawi, Mozambique, South Africa, Zambia and Zimbabwe in 2005 to 2018. We examined the frequency of CD4 and VL testing, the percentage of adults with CD4 or VL tests, and among those having a test, the percentage starting ART with advanced HIV disease (CD4 count <200 cells/mm Among 502,456 adults, the percentage with CD4 testing at ART initiation decreased from a high of 78.1% in 2008 to a low of 38.0% in 2017; the probability declined by 14% each year (odds ratio (OR) 0.86; 95% CI 0.86 to 0.86). Frequency of CD4 testing also declined. The percentage starting ART with advanced HIV disease declined from 83.3% in 2005 to 23.5% in 2018; each year the probability declined by 20% (OR 0.80; 95% CI 0.80 to 0.81). VL testing after starting ART varied; 61.0% of adults in South Africa and 10.7% in Malawi were tested, but fewer than 2% were tested in the other four countries. The probability of VL testing after ART start increased only modestly each year (OR 1.06; 95% CI 1.05 to 1.06). The percentage with unsuppressed VL was 8.6%. There was no evidence of a decrease in unsuppressed VL over time (OR 1.00; 95% CI 0.99 to 1.01). CD4 cell counting declined over time, including testing at the start of ART, despite the fact that many patients still initiated ART with advanced HIV disease. Without CD4 testing and expanded VL testing many patients with advanced HIV disease and treatment failure may go undetected, threatening the effectiveness of ART in sub-Saharan Africa.
Identifiants
pubmed: 32640106
doi: 10.1002/jia2.25546
pmc: PMC7343336
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25546Subventions
Organisme : NIAAA NIH HHS
ID : U01AI069924
Pays : United States
Organisme : NIDA NIH HHS
ID : U01AI069924
Pays : United States
Organisme : Swiss National Science Foundation
ID : 174281
Pays : Switzerland
Organisme : NIDDK NIH HHS
ID : U01AI069924
Pays : United States
Organisme : NIMH NIH HHS
ID : U01AI069924
Pays : United States
Organisme : NICHD NIH HHS
ID : U01AI069924
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01AI069924
Pays : United States
Organisme : NLM NIH HHS
ID : U01AI069924
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCI NIH HHS
ID : U01AI069924
Pays : United States
Organisme : FIC NIH HHS
ID : U01AI069924
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.
Références
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):319-329
pubmed: 28708808
Curr Opin HIV AIDS. 2017 Mar;12(2):123-128
pubmed: 28059957
PLoS Med. 2017 Apr 4;14(4):e1002253
pubmed: 28376085
J Epidemiol Community Health. 2016 Jun;70(6):549-55
pubmed: 26700300
J Int AIDS Soc. 2020 Jul;23(7):e25546
pubmed: 32640106
J Virus Erad. 2018 Nov 15;4(Suppl 2):9-15
pubmed: 30515309
Clin Infect Dis. 2018 Mar 5;66(6):893-903
pubmed: 29373672
PLoS Med. 2013;10(4):e1001418
pubmed: 23585736
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
BMJ Open. 2020 May 15;10(5):e035246
pubmed: 32414825
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1287-90
pubmed: 26605986
Int J Epidemiol. 2007 Apr;36(2):294-301
pubmed: 17213214
Int J Epidemiol. 2012 Oct;41(5):1256-64
pubmed: 21593078
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
J Int AIDS Soc. 2014 Jun 12;17:18932
pubmed: 24929097
Int J Epidemiol. 2007 Oct;36(5):969-76
pubmed: 17846055
PLoS Med. 2014 Sep 09;11(9):e1001718
pubmed: 25203931
Lancet. 2010 Aug 7;376(9739):449-57
pubmed: 20638120